Compare NVDA & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVDA | NVO |
|---|---|---|
| Founded | 1993 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9T | 199.4B |
| IPO Year | 1998 | 2001 |
| Metric | NVDA | NVO |
|---|---|---|
| Price | $229.14 | $39.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 38 | 11 |
| Target Price | ★ $266.24 | $51.00 |
| AVG Volume (30 Days) | ★ 110.2M | 9.9M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | 0.02% | ★ 3.19% |
| EPS Growth | ★ 66.67 | N/A |
| EPS | ★ 4.85 | N/A |
| Revenue | ★ $215,938,000,000.00 | N/A |
| Revenue This Year | $73.22 | N/A |
| Revenue Next Year | $31.16 | $3.70 |
| P/E Ratio | $46.86 | ★ $13.60 |
| Revenue Growth | ★ 65.47 | N/A |
| 52 Week Low | $164.27 | $35.12 |
| 52 Week High | $236.54 | $64.16 |
| Indicator | NVDA | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 29.93 |
| Support Level | $208.32 | $38.02 |
| Resistance Level | $232.39 | $41.41 |
| Average True Range (ATR) | 4.55 | 0.90 |
| MACD | 0.29 | -0.45 |
| Stochastic Oscillator | 73.42 | 3.88 |
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence to run large language models. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.